Welcome to our dedicated page for Pliant Therapeutics SEC filings (Ticker: PLRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biopharmaceutical company focused on integrin-based therapeutics. These regulatory documents offer detailed information on the company’s financial condition, clinical development activities, risk factors and corporate governance.
Through periodic reports such as Forms 10-Q and 10-K, Pliant describes research and development spending, progress in programs like bexotegrast (PLN-74809) for idiopathic pulmonary fibrosis, PLN-101095 for solid tumors and PLN-101325 for muscular dystrophies, as well as broader platform efforts in integrin-based drug discovery. Current reports on Form 8-K, including those referenced in the provided data, disclose specific material events such as financial results for a quarter, voluntary prepayment and termination of a loan agreement, changes in executive leadership roles and other significant corporate actions.
Investors can also review filings that discuss strategic realignments of workforce and operations, cash runway considerations and references to risk factors and management’s discussion and analysis sections, which Pliant points to in its press releases. For those tracking equity and governance details, the company’s registration of common stock and related rights on The Nasdaq Stock Market LLC is reflected in its SEC submissions.
On Stock Titan, these filings are available alongside AI-powered summaries that highlight key points, helping readers interpret lengthy documents such as annual and quarterly reports or event-driven 8-Ks. Real-time updates from the SEC’s EDGAR system, combined with structured access to filings related to financial results, material agreements and leadership changes, allow users to follow how Pliant’s disclosures develop over time.
Pliant Therapeutics, Inc. has filed a shelf registration to offer up to $300,000,000 of securities, which may include debt securities, common stock, preferred stock, units and warrants. The prospectus also includes an at-the-market offering under a Sales Agreement with Leerink Partners LLC to sell up to $50,000,000 of common stock.
The prospectus describes general terms for future offerings and states proceeds will be used for general corporate purposes, including research and development and clinical programs. The registration incorporates prior SEC filings by reference and notes the company’s common stock trades on Nasdaq under the symbol PLRX (closing price $1.17 on March 27, 2026).
Pliant Therapeutics, Inc. updated its at-the-market stock offering arrangements. The company has a Sales Agreement with Leerink Partners LLC that allows it to offer and sell common stock with an aggregate offering price of up to $50.0 million under an at-the-market prospectus. Effective March 27, 2026, it terminated a prior Controlled Equity Offering℠ Sales Agreement with Cantor Fitzgerald & Co., with no termination penalties and no shares having been sold under the 2021 agreement.
Pliant Therapeutics reported fourth quarter 2025 results alongside a major update on its oncology pipeline. Lead candidate PLN-101095, an oral dual-selective αvβ8/αvβ1 inhibitor, showed deep and durable responses in a Phase 1 trial in immune checkpoint inhibitor–refractory solid tumors, including one confirmed complete response and three partial responses among 10 secondary ICI refractory patients. The company has begun an accelerated development plan with a Phase 1b indication expansion trial in non-small cell lung cancer, clear cell renal cell carcinoma and tumors with high tumor mutational burden, and Phase 1 data will be presented at the AACR Annual Meeting 2026.
Research and development expenses fell to $15.6 million from $38.8 million in the prior-year quarter, and general and administrative expenses declined to $8.0 million from $14.5 million, mainly due to discontinuation of BEACON-IPF and workforce restructuring. Quarterly net loss narrowed to $23.6 million from $49.7 million, and full-year 2025 net loss was $149.3 million versus $210.3 million in 2024. As of December 31, 2025, Pliant held $192.4 million in cash, cash equivalents and short-term investments, which it expects to fund operations into the second half of 2028.
Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing integrin-based drugs, with a primary focus on oncology. Its wholly owned lead candidate, PLN-101095, is an oral dual inhibitor of αvβ8 and αvβ1 integrins for solid tumors resistant to immune checkpoint inhibitors.
In a Phase 1 open-label dose-escalation trial, PLN-101095 plus pembrolizumab produced one confirmed complete response and three partial responses among ten secondary ICI-refractory patients, with 60% showing stable disease or tumor reduction. Pliant plans a Phase 1b indication-expansion trial in non-small cell lung cancer and other tumor types in 2026.
The company built a proprietary library of over 15,000 integrin-binding molecules supporting early programs, including siRNA delivery to specific cell types. Pliant discontinued development of bexotegrast in idiopathic pulmonary fibrosis after a Phase 2b safety imbalance, and currently sees no cost-effective path forward in primary sclerosing cholangitis.
Pliant Therapeutics has extended its stockholder rights plan by one year. The company and Computershare Trust Company, N.A., amended their Stockholder Rights Agreement so that the associated rights now expire at 5:00 p.m. New York City time on March 11, 2027, instead of March 11, 2026.
The plan is intended to make it harder for any person, entity or group to gain control of the company through open market share purchases without paying all stockholders an appropriate control premium or giving the board enough time to evaluate alternatives. The company states the change was not made in response to any specific takeover offer and is not meant to block mergers or other business combinations approved by the board.
Pliant Therapeutics, Inc. received an amended Schedule 13G/A from Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen reporting a small ownership position. As of the close of business on December 31, 2025, the group beneficially owned 46,537 shares of common stock, representing 0.1% of the outstanding class.
The filing explains that the shares are held by an investment fund managed by Point72 Asset Management, with Point72 Capital Advisors as its general partner and Mr. Cohen controlling both entities. The filers state that the securities were not acquired and are not held for the purpose of changing or influencing control of Pliant Therapeutics.
Woodline Partners LP filed an amended Schedule 13G/A reporting its beneficial ownership of Pliant Therapeutics common stock. Woodline reports beneficial ownership of 2,026,191 shares, representing 3.3% of the outstanding common stock, based on 61,449,385 shares outstanding as of November 1, 2025.
The shares are held through Woodline Master Fund LP, for which Woodline Partners serves as investment adviser, with sole voting and dispositive power over all reported shares. Woodline certifies the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Pliant Therapeutics.
Kenneth Griffin and affiliated Citadel entities report a 5.0% beneficial ownership stake in Pliant Therapeutics, Inc. common stock. The group may be deemed to beneficially own 3,042,133 Shares, based on 61,449,385 Shares outstanding as of November 1, 2025.
Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may each be deemed to beneficially own 2,099,798 Shares, while Citadel Securities LLC may be deemed to own 913,609 Shares. All reporting persons have shared, but not sole, voting and dispositive power over their respective positions and certify the holdings are not for the purpose of changing or influencing control of Pliant.
Citadel-affiliated entities and Kenneth Griffin report a significant but sub-5% passive stake in Pliant Therapeutics, Inc. They collectively may be deemed to beneficially own 3,037,695 common shares, equal to 4.9% of the company’s stock, based on 61,449,385 shares outstanding as of November 1, 2025.
The shares are held through Citadel Advisors LLC, Citadel Advisors Holdings LP, Citadel GP LLC, Citadel Securities LLC, Citadel Securities Group LP, Citadel Securities GP LLC, and related vehicles. All voting and dispositive powers are shared, and the reporting persons certify the holdings were not acquired to change or influence control of Pliant.
Pliant Therapeutics reported that its Chief Financial Officer, Keith Lamont Cummings, received a new stock option grant. The option allows him to buy 400,000 shares of common stock at an exercise price of $1.30 per share, expiring on January 22, 2036. According to the vesting terms, 1/48th of the shares vest and become exercisable on each monthly anniversary of January 1, 2026, as long as he continues to serve the company. After this award, he holds 400,000 stock options directly.